Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Turkova

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
The Lancet. HIV|July 22, 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trialAnna Turkova, Hylke Waalewijn, Man K Chan, et al.
Trials|April 21, 2018
Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trialChishala Chabala, Anna Turkova, Margaret J Thomason, et al.
British Journal of Clinical Pharmacology|September 4, 2024
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patientsTom G Jacobs, Hylke Waalewijn, Lily Houlden, et al.
Plos One|April 24, 2018
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trialAnna Turkova, Cecilia L Moore, Karina Butler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2026
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trialJames Wyncoll, Rujirek Kamolrattana, Moherndran Archary, et al.
BMC Infectious Diseases|January 15, 2021
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosingCecilia L Moore, Anna Turkova, Hilda Mujuru, et al.
The Lancet. HIV|September 2, 2022
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trialPauline Amuge, Abbas Lugemwa, Ben Wynne, et al.
The Lancet. Child & Adolescent Health|January 24, 2026
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Avy Violari, et al.
Antiviral Therapy|August 27, 2022
Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and ThailandEuropean Pregnancy And Paediatric Infections Cohort Collaboration Eppicc, Alex Lyons, Lindsay Thompson, et al.
Open Forum Infectious Diseases|June 3, 2026
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized TrialHilda Angela Mujuru, Ellen White, Adeodata R Kekitiinwa, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
The Lancet. HIV|July 22, 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trialAnna Turkova, Hylke Waalewijn, Man K Chan, et al.
Trials|April 21, 2018
Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trialChishala Chabala, Anna Turkova, Margaret J Thomason, et al.
British Journal of Clinical Pharmacology|September 4, 2024
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patientsTom G Jacobs, Hylke Waalewijn, Lily Houlden, et al.
Plos One|April 24, 2018
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trialAnna Turkova, Cecilia L Moore, Karina Butler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2026
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trialJames Wyncoll, Rujirek Kamolrattana, Moherndran Archary, et al.
BMC Infectious Diseases|January 15, 2021
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosingCecilia L Moore, Anna Turkova, Hilda Mujuru, et al.
The Lancet. HIV|September 2, 2022
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trialPauline Amuge, Abbas Lugemwa, Ben Wynne, et al.
The Lancet. Child & Adolescent Health|January 24, 2026
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Avy Violari, et al.
Antiviral Therapy|August 27, 2022
Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and ThailandEuropean Pregnancy And Paediatric Infections Cohort Collaboration Eppicc, Alex Lyons, Lindsay Thompson, et al.
Open Forum Infectious Diseases|June 3, 2026
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized TrialHilda Angela Mujuru, Ellen White, Adeodata R Kekitiinwa, et al.
Pageof 9